Upfront costs challenge proposed hepatitis C legislation

Despite a clear consensus on the urgent need to combat hepatitis C, the United States is falling dangerously behind other developed nations in expanding access to life-saving cures. While England is on track to eliminate the disease as a public health threat within years, American efforts are stalled in a gridlocked Congress, hampered by partisan divisions and a troubling focus on short-term costs over long-term savings.

“

It comes back to money and political will. How do you convince Congress, especially these days — a very divided Congress — to make this a priority?

The proposed 'Cure Hepatitis C Act,' championed by bipartisan leaders like Senator Bill Cassidy, offers a comprehensive national plan for testing and treatment. This legislation, however, faces a significant obstacle: an initial $10 billion federal investment. While the Congressional Budget Office projects substantial savings—$6.6 billion over a decade—by preventing costly complications like liver failure and cancer, lawmakers are struggling to approve the upfront expenditure. This highlights a critical disconnect: a failure to prioritize preventative healthcare and understand that investing in cures now yields significant financial and human returns later.

“

That has always been a barrier — getting lawmakers to understand the need to invest on the prevention side when there’s an upfront cost.

Furthermore, the Trump administration's apparent pullback from infectious disease priorities dims prospects for a coordinated federal response. Adding to the complexity, certain provisions limiting access for undocumented immigrants have complicated support in the House and raised concerns among community health centers. The World Health Organization's call to end hepatitis C by 2030 seems increasingly aspirational for the US, given the current legislative inertia. From our perspective, this isn't just a policy failure; it's a moral one. Every day lost means more lives needlessly lost and more taxpayer money ultimately spent on managing the consequences of untreated disease. This is a fight for public health that demands immediate action and a clear-eyed understanding of the value of preventative investment.

“

We really need to enact this as soon as possible. Every day, more lives are lost that could have been saved, and we’re also not achieving the savings from the taxpayer that we should.